Werewolf Therapeutics (HOWL) Total Liabilities (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Total Liabilities of $7.9 million for Q2 2026, down 84.61% year-over-year from $51.1 million in Q2 2025, and down 82.84% on a QoQ basis from $45.8 million in Q1 2026.
Werewolf Therapeutics (HOWL) Total Liabilities (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Total Liabilities for 7 years, with the latest figure at $7.9 million in Q2 2026.
- Total Liabilities for Q2 2026 came in at $7.9 million, down 84.61% year-over-year; the trailing twelve-month figure through Jun 2026 was $7.9 million (down 84.61% YoY), and the FY2025 annual result was $44.6 million, down 16.71% from the prior year.
- Total Liabilities fell to $7.9 million in Q2 2026, from $45.8 million in the prior quarter.
- Over five years, Total Liabilities peaked at $74.0 million in Q1 2023 and troughed at $7.9 million in Q2 2026.
- A 5-year average of $49.0 million and a median of $50.0 million in 2025 frame the typical range for Total Liabilities.
- The widest annual swing landed in 2022, when Total Liabilities jumped 413.29%; it then plunged 84.61% in 2026.
- A 5-year view of Total Liabilities shows it stood at $37.9 million in 2022, then surged by 67.4% to $63.5 million in 2023, then slipped by 15.63% to $53.5 million in 2024, then retreated by 16.71% to $44.6 million in 2025, then tumbled by 82.37% to $7.9 million in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $7.9 million in Q2 2026, $45.8 million in Q1 2026, and $44.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.54 Bn | 130.69 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.89 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.65 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 56.53 Bn | 51.39 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 10.03 Bn |
| 10 | Werewolf Therapeutics | 42.78 Mn | 42.78 Mn | - | 7.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.86 Mn |
| Mar 31, 2026 | 45.82 Mn |
| Dec 31, 2025 | 44.59 Mn |
| Sep 30, 2025 | 50.01 Mn |
| Jun 30, 2025 | 51.10 Mn |
| Mar 31, 2025 | 49.93 Mn |
| Dec 31, 2024 | 53.54 Mn |
| Sep 30, 2024 | 50.66 Mn |
| Jun 30, 2024 | 49.69 Mn |
| Mar 31, 2024 | 60.01 Mn |
| Dec 31, 2023 | 63.46 Mn |
| Sep 30, 2023 | 63.94 Mn |
| Jun 30, 2023 | 66.64 Mn |
| Mar 31, 2023 | 74.00 Mn |
| Dec 31, 2022 | 37.91 Mn |
| Sep 30, 2022 | 41.48 Mn |
| Jun 30, 2022 | 45.49 Mn |
| Mar 31, 2022 | 25.31 Mn |
| Dec 31, 2021 | 26.46 Mn |
| Sep 30, 2021 | 9.07 Mn |